| Dr Jennifer Lynn Pepper, MD | |
|
6901 Medical Parkway, Waco, TX 76712 | |
| (254) 751-4146 | |
| (254) 751-4283 |
| Full Name | Dr Jennifer Lynn Pepper |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 30 Years |
| Location | 6901 Medical Parkway, Waco, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245334853 | NPI | - | NPPES |
| 136880513 | Medicaid | TX | |
| 8S0954 | Other | TX | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | TXBJ8710 (Texas) | Secondary |
| 207P00000X | Emergency Medicine | J8710 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Legacy Urgent Care Pa | 3072679828 | 119 |
News Archive
A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute, showed that a new drug called MM-398, given in combination with 5-flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously-treated pancreatic cancer.
A new study has been published on the medRxiv* preprint server which focuses on validating the serological assays using a large cohort of healthcare workers.
Results of two studies funded by Project A.L.S. and appearing in the advance online publication of Nature Neuroscience demonstrate that embryonic stem cells may provide a new tool for studying disease mechanisms and for identifying drugs to slow ALS, also known as Lou Gehrig's disease.
In an effort to lower medical costs, identify patients at risk for injury, and speed patient recovery, scientists will attempt to identify a molecular signal that indicates severity of brain-injury during a $4 million, five-year federal grant to Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix Children's Hospital and the Translational Genomics Research Institute (TGen).
Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, today announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialize biomarkers, targets and medicines for inflammatory bowel disease.
› Verified 3 days ago
| Entity Name | Legacy Urgent Care Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568622272 PECOS PAC ID: 3072679828 Enrollment ID: O20090304000140 |
News Archive
A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute, showed that a new drug called MM-398, given in combination with 5-flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously-treated pancreatic cancer.
A new study has been published on the medRxiv* preprint server which focuses on validating the serological assays using a large cohort of healthcare workers.
Results of two studies funded by Project A.L.S. and appearing in the advance online publication of Nature Neuroscience demonstrate that embryonic stem cells may provide a new tool for studying disease mechanisms and for identifying drugs to slow ALS, also known as Lou Gehrig's disease.
In an effort to lower medical costs, identify patients at risk for injury, and speed patient recovery, scientists will attempt to identify a molecular signal that indicates severity of brain-injury during a $4 million, five-year federal grant to Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix Children's Hospital and the Translational Genomics Research Institute (TGen).
Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, today announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialize biomarkers, targets and medicines for inflammatory bowel disease.
› Verified 3 days ago
| Entity Name | Premier Physicians - Ii Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801204656 PECOS PAC ID: 9234416744 Enrollment ID: O20170511000584 |
News Archive
A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute, showed that a new drug called MM-398, given in combination with 5-flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously-treated pancreatic cancer.
A new study has been published on the medRxiv* preprint server which focuses on validating the serological assays using a large cohort of healthcare workers.
Results of two studies funded by Project A.L.S. and appearing in the advance online publication of Nature Neuroscience demonstrate that embryonic stem cells may provide a new tool for studying disease mechanisms and for identifying drugs to slow ALS, also known as Lou Gehrig's disease.
In an effort to lower medical costs, identify patients at risk for injury, and speed patient recovery, scientists will attempt to identify a molecular signal that indicates severity of brain-injury during a $4 million, five-year federal grant to Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix Children's Hospital and the Translational Genomics Research Institute (TGen).
Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, today announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialize biomarkers, targets and medicines for inflammatory bowel disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jennifer Lynn Pepper, MD Po Box 2589, Waco, TX 76702-2589 Ph: (254) 751-4146 | Dr Jennifer Lynn Pepper, MD 6901 Medical Parkway, Waco, TX 76712 Ph: (254) 751-4146 |
News Archive
A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute, showed that a new drug called MM-398, given in combination with 5-flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously-treated pancreatic cancer.
A new study has been published on the medRxiv* preprint server which focuses on validating the serological assays using a large cohort of healthcare workers.
Results of two studies funded by Project A.L.S. and appearing in the advance online publication of Nature Neuroscience demonstrate that embryonic stem cells may provide a new tool for studying disease mechanisms and for identifying drugs to slow ALS, also known as Lou Gehrig's disease.
In an effort to lower medical costs, identify patients at risk for injury, and speed patient recovery, scientists will attempt to identify a molecular signal that indicates severity of brain-injury during a $4 million, five-year federal grant to Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix Children's Hospital and the Translational Genomics Research Institute (TGen).
Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, today announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialize biomarkers, targets and medicines for inflammatory bowel disease.
› Verified 3 days ago
Dr. Foy Edward Dark Iii, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1201 Hewitt Dr, Suite 203, Waco, TX 76712 Phone: 254-666-3627 Fax: 243-732-6125 | |
Dr. Timothy Michael Welter, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3000 Herring Ave, Waco, TX 76708 Phone: 254-202-8611 | |
Dr. Michelle Marie Law, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5400 Crosslake Pkwy, Waco, TX 76712 Phone: 254-420-2336 | |
Brennon Edward Barajas, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Hillcrest Medical Blvd, Waco, TX 76712 Phone: 915-474-4415 | |
Dr. Joel David Mendez, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 6901 Medical Pkwy, Waco, TX 76712 Phone: 832-814-7136 | |
Dr. Weldon Louis Kunkel, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 6901 Medical Parkway, Waco, TX 76712 Phone: 254-751-4146 Fax: 254-751-4283 | |
Dr. Harvey Robert Chen, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7125 New Sanger Ave Ste A, Waco, TX 76712 Phone: 254-399-5400 Fax: 254-772-8669 |